University of Tasmania
Browse

File(s) not publicly available

Technology evaluation: MRA, Chugai

journal contribution
posted on 2023-05-21, 20:00 authored by Chang-Hai DingChang-Hai Ding, Graeme JonesGraeme Jones
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

History

Publication title

Current Opinion in Molecular Therapeutics

Volume

5

Pagination

64-9

ISSN

1464-8431

Department/School

Menzies Institute for Medical Research

Publisher

Current Drugs Ltd

Place of publication

London, England

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Categories

    Keywords

    No keyword provided

    Licence

    In Copyright

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC